DUPILUMAB (Dupixent) prior authorization at Aetna
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Aetna requires Interleukin-4 Receptor alpha Antagonist prior-authorization documentation for DUPILUMAB (Dupixent): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Aetna reviews DUPILUMAB (Dupixent) prior authorizations against its medical policy for Interleukin-4 Receptor alpha Antagonist. Aetna-specific context: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-4 Receptor alpha Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Aetna's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
DUPILUMAB (Dupixent)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Severity threshold (EASI score requirements)
- Step therapy requiring topicals first
- Indication restrictions (atopic dermatitis vs asthma vs nasal polyposis)
Multiple FDA indications: atopic dermatitis, asthma, eosinophilic esophagitis, nasal polyposis, prurigo nodularis. Each indication has separate prior auth criteria.
Manufacturer patient-assistance program: Dupixent MyWay — relevant when an Aetna denial sticks and the patient needs bridge access while appealing.
How Aetna approaches Biologic drugs (mAbs and biosimilars) PAs
For DUPILUMAB (DUPIXENT), check whether the current Aetna Biologic drugs (mAbs and biosimilars) policy cites step therapy on specialty drugs. Pharmacy-benefit review for DUPILUMAB (DUPIXENT) at Aetna is routed through CVS Caremark (parent CVS Health since 2018). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Aetna; if denied, use the filing date and route printed on that denial notice. Aetna's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Aetna is domiciled in CT, so unresolved appeals escalate to the CT insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.aetnaprovider.com) with the same packet plus an applicable, current clinical source supporting DUPILUMAB (Dupixent)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an Aetna denial on DenialHelp.
Contact Aetna
- Provider portal: https://www.aetnaprovider.com
Frequently asked questions
What documentation does Aetna need for DUPILUMAB (Dupixent) prior auth?
Aetna's typical PA packet for DUPILUMAB (Dupixent): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-4 Receptor alpha Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Aetna?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for DUPILUMAB (Dupixent) at Aetna?
Preparation scenarios to check against the current notice and policy include: UM-2575 medical necessity denials; Prior auth absent; Step therapy on specialty drugs. These are not measured frequency claims. For DUPILUMAB (Dupixent), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Aetna typically require before approving DUPILUMAB (DUPIXENT)?
Aetna's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For DUPILUMAB (DUPIXENT), attach the specific disease-activity instrument Aetna accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through CVS Caremark (parent CVS Health since 2018). External-review escalation for Aetna fully-insured policies sits with the CT insurance department.
How do I prep for a peer-to-peer with Aetna on DUPILUMAB (Dupixent)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the DUPILUMAB (Dupixent) PA packet
Open ApprovalHelp — generate a DUPILUMAB (Dupixent) prior-auth packet tailored to Aetna's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com